Whitehawk Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $249.49M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-0.20 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.32 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-0.26 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.76 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $7.10M | $1.83 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | During market hours | $7.20M | $-0.67 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $7.20M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
Press releases
Announcements Whitehawk Therapeutics filed with the SEC
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Other events · EX-99.1 to Form 8-K
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
Material agreement · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Aadi Bioscience Transforms with In-Licensing of Novel ADC
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
December 20, 2024 Strategic Update
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab -Sirolimus
Other events · EX-99.1 to Form 8-K
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K/A
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results and Operational Update for the
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
Results of operations · Executive or director change · EX-99.2 to Form 8-K
Aadi Bioscience Announces Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Aadi Bioscience Announces Planned Leadership Transition
Results of operations · Executive or director change · EX-99.2 to Form 8-K
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aadi Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aadi Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K